Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laure Chene

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
The Journal of Pediatrics|September 11, 2023
Parsnips and PhytophotodermatitisLaure Chene, Christine Chiaverini, Stéphane Kandemir, et al.
Cancers|December 23, 2023
A Comparative Multicenter Cohort Study Evaluating the Long-Term Influence of the Strict Lockdown during the First COVID-19 Wave on Lung Cancer Patients (ARTEMISIA Trial)Olivier Molinier, Camille Guguen, Marie Marcq, et al.
Cancer Immunology, Immunotherapy : CII|November 28, 2021
Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumabMathilde Bureau, Thierry Chatellier, Tanguy Perennec, et al.
Frontiers in Oncology|June 8, 2026
Case Report: Pembrolizumab unmasks a capillary leak syndrome with chylothorax in early TNBCNaïla Benkalfate, Ghazi Hadjamara, Caroline Petorin, et al.
The European Respiratory Journal|August 29, 2020
Functional assessment and phenotypic heterogeneity of <i>SFTPA1</i> and <i>SFTPA2</i> mutations in interstitial lung diseases and lung cancerMarie Legendre, Afifaa Butt, Raphaël Borie, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
The Journal of Pediatrics|September 11, 2023
Parsnips and PhytophotodermatitisLaure Chene, Christine Chiaverini, Stéphane Kandemir, et al.
Cancers|December 23, 2023
A Comparative Multicenter Cohort Study Evaluating the Long-Term Influence of the Strict Lockdown during the First COVID-19 Wave on Lung Cancer Patients (ARTEMISIA Trial)Olivier Molinier, Camille Guguen, Marie Marcq, et al.
Cancer Immunology, Immunotherapy : CII|November 28, 2021
Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumabMathilde Bureau, Thierry Chatellier, Tanguy Perennec, et al.
Frontiers in Oncology|June 8, 2026
Case Report: Pembrolizumab unmasks a capillary leak syndrome with chylothorax in early TNBCNaïla Benkalfate, Ghazi Hadjamara, Caroline Petorin, et al.
The European Respiratory Journal|August 29, 2020
Functional assessment and phenotypic heterogeneity of <i>SFTPA1</i> and <i>SFTPA2</i> mutations in interstitial lung diseases and lung cancerMarie Legendre, Afifaa Butt, Raphaël Borie, et al.
Pageof 1